Bottom line
PPH vs FPHAX: the short answer
PPH (VanEck Pharmaceutical ETF) and FPHAX (Pharmaceuticals Portfolio) share a meaningful slice of their top holdings — about 41% by weight.
But FPHAX is far broader, holding 57 positions to 26 for PPH, so beyond the top names it adds exposure PPH doesn't have.
PPH is cheaper at 0.36% vs 0.67% — a difference of $31 a year per $10,000 invested.
Over five years, FPHAX returned +12.6% a year vs +11.3% for PPH (reporting dates differ).
Updated Nov 19, 2026
PPH vs FPHAX side by side
| PPH | FPHAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | VanEck | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.36% | 0.67% |
| Annual cost per $10k | $36 | $67 |
| 10-yr cost on $10k (prospectus) | $456 | $835 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +21.9% | +30.3% |
| 5-yr return (annualized) | +11.3% | +12.6% |
| 10-yr return (annualized) | +6.7% | +10.0% |
| Best quarter | +16.5% | +18.5% |
| Worst quarter | −15.0% | −13.6% |
| Net assets (fund) | $879.5M | $1.5B |
| Number of holdings | 26 | 57 |
| Portfolio turnover | 3% | 77% |
| Returns as of | Dec 31, 2025 | Apr 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PPH | FPHAX | Difference |
|---|---|---|---|
| 2025 | +21.9% | +30.3% | −8.4% |
| 2024 | +8.1% | +9.4% | −1.3% |
| 2023 | +6.9% | +12.5% | −5.6% |
| 2022 | +2.6% | +1.0% | +1.7% |
| 2021 | +18.3% | +11.8% | +6.5% |
| 2020 | +5.2% | +11.1% | −5.9% |
| 2019 | +19.1% | +31.6% | −12.5% |
| 2018 | −5.7% | +5.8% | −11.5% |
| 2017 | +15.4% | +10.7% | +4.7% |
| 2016 | −17.8% | −16.3% | −1.5% |
Source: Fund prospectus bar charts
Holdings overlap
9 of PPH's top 25 holdings also appear in FPHAX's top 25.
| Holding | PPH | FPHAX |
|---|---|---|
| Eli Lilly & Co | 20.23% | 28.78% |
| Merck & Co Inc | 9.85% | 4.74% |
| Gsk Plc | 4.42% | 8.17% |
| Johnson & Johnson | 4.35% | 3.77% |
| AstraZeneca PLC | 4.33% | 4.22% |
| Viatris Inc | 1.10% | 5.45% |
| Jazz Pharmaceuticals PLC | 1.08% | 4.09% |
| Axsome Therapeutics Inc | 0.77% | 1.08% |
| Elanco Animal Health Inc | 0.35% | 4.15% |
Source: SEC Form N-PORT
PPH top 10
- Eli Lilly & Co — 20.23%
- Novartis AG — 10.63%
- Merck & Co Inc — 9.85%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Pfizer Inc — 4.51%
- Bristol-Myers Squibb Co — 4.47%
- Gsk Plc — 4.42%
- Johnson & Johnson — 4.35%
- AstraZeneca PLC — 4.33%
FPHAX top 10
- ELI LILLY and CO — 28.78%
- Gsk Plc — 8.17%
- Viatris Inc — 5.45%
- Ucb Sa — 5.09%
- MERCK and CO INC — 4.74%
- Roche Holding Ag — 4.54%
- Legend Biotech Corp — 4.53%
- Astrazeneca Plc — 4.22%
- Elanco Animal Health Inc — 4.15%
- Jazz Pharmaceuticals Plc — 4.09%
FAQ
What is the difference between PPH and FPHAX?
Which is cheaper, PPH or FPHAX?
Should I own both PPH and FPHAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.